


**CERTIFICATE OF MAILING**

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Stephen C. D'Amico  
Type or print name

  
Signature

10-13-04  
Date

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

IN RE APPLICATION OF

Art Unit: 1745

BATTAGLINO ET AL.

APPLICATION NO: 10/712,615

FILED: NOVEMBER 13, 2003

FOR: A NOVEL HUMAN G-PROTEIN COUPLED RECEPTOR,  
HGPRBMY8, EXPRESSED HIGHLY IN BRAIN

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450


**INFORMATION DISCLOSURE STATEMENT**

Sir:

Applicants believe this paper is being filed before the mailing date of a first Office Action on the merits, and so under 37 C.F.R. §1.97(b)(3) no fees are required. If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-3880.

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.


Copies of these references are enclosed herewith.



The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).


Respectfully submitted,

Bristol-Myers Squibb Company  
Patent Department  
P.O. Box 4000  
Princeton, NJ 08543-4000  
(609) 252-5289

  
\_\_\_\_\_  
Stephen C. D'Amico  
Agent for Applicants  
Reg. No. 46,652

Date: *10-13-04*

## INFORMATION DISCLOSURE CITATION

ATTY. DOCKET NO.  
D0047A CIP  
APPLICATION NO.  
10/712,615  
APPLICANT  
BATTAGLINO ET AL.  
FILING DATE  
NOVEMBER 13, 2003Group  
1745

(Use several sheets if necessary)

## U.S. PATENT APPLICATION PUBLICATIONS

EXAMINER INITIAL		U.S. APPLICATION DOCUMENT	DATE OF PUBLICATION	NAME	CLASS	SUBCLASS	FILING DATE
	AA	2003/0096751	5/22/03	Ramanathan et al.			
	AB	2003/0152977	8/14/03	Ramanathan et al.			
	AC	2004/0018976	1/29/04	Feder et al.			
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	AM	WO 02/28901	4/11/02	PCT			<input type="checkbox"/>	<input type="checkbox"/>
	AN	WO 02/059151	8/1/02	PCT			<input type="checkbox"/>	<input type="checkbox"/>
	AO	WO 02/059304	8/1/02	PCT			<input type="checkbox"/>	<input type="checkbox"/>
	AP						<input type="checkbox"/>	<input type="checkbox"/>
	AQ						<input type="checkbox"/>	<input type="checkbox"/>

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

AR	NCBI Entrez Accession No. AAL26486 (gi:16566341), Lee, D.K. et al., November 1, 2001
AS	NCBI Entrez Accession No. AC016468 (gi:10045369), Birren, B. et al., September 9, 2000
AT	NCBI Entrez Accession No. AL390879 (gi:14575268), Lawlor, S., July 3, 2001

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

**INFORMATION DISCLOSURE CITATION**

(Use several sheets if necessary)

ATTY. DOCKET NO.  
D0047A CIP  
APPLICATION NO.  
10/712,615  
APPLICANT  
BATTAGLINO ET AL.  
FILING DATE  
NOVEMBER 13, 2003Group  
1745**OTHER DOCUMENTS** (Including Author, Title, Date, Pertinent pages, Etc.)

	2AA	NCBI Entrez Accession No. AX080495 (gi:13162149), Deleersnijder, W. et al., February 26, 2001
	2AB	NCBI Entrez Accession No. AX148250 (gi:14347146), Chen, R. et al., June 8, 2001
	2AC	NCBI Entrez Accession No. CAC33098 (gi:13162150), Deleersnijder, W. et al., February 26, 2001
	2AD	NCBI Entrez Accession No. NM_000818 (gi:4503874), Dracheva, S. et al., August 23, 2004
	2AE	NCBI Entrez Accession No. XP_066653 (gi:17485708), NCBI Annotation Project, December 11, 2001
	2AF	Swiss-Prot Accession No. O02824, Release 36, July 1998
	2AG	Swiss-Prot Accession No. O42385, Release 39, May 2000
	2AH	Swiss-Prot Accession No. O77621, Release 38, July 1999
	2AI	Swiss-Prot Accession No. O96716, Release 10, May 1999
	2AJ	Swiss-Prot Accession No. P08908, Release 09, November 1988
	2AK	Swiss-Prot Accession No. P17200, Release 15, August 1990
	2AL	Swiss-Prot Accession No. P18130, Release 16, November 1990
	2AM	Swiss-Prot Accession No. P25100, Release 22, May 1992
	2AN	Swiss-Prot Accession No. P35348, Release 29, June 1994

**EXAMINER****DATE CONSIDERED**

\*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

FORM PTO-1449  
(REV. 7-85)U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE**INFORMATION DISCLOSURE CITATION**

(Use several sheets if necessary)

ATTY. DOCKET NO.  
D0047A CIP  
APPLICATION NO.  
10/712,615  
APPLICANT  
BATTAGLINO ET AL.  
FILING DATE  
NOVEMBER 13, 2003Group  
1745**OTHER DOCUMENTS** (Including Author, Title, Date, Pertinent pages, Etc.)

3AA	Swiss-Prot Accession No. P43140, Release 32, November 1995
3AB	Swiss-Prot Accession No. P97714, Release 36, July 1998
3AC	Swiss-Prot Accession No. P97718, Release 36, July 1998
3AD	Swiss-Prot Accession No. Q19084, Release 36, July 1998
3AE	Swiss-Prot Accession No. Q25414, Release 35, November 1997
3AF	Swiss-Prot Accession No. Q64264, Release 35, November 1997
3AG	Swiss-Prot Accession No. Q8N6U8, Release 44, July 2004
3AH	Swiss-Prot Accession No. Q91175, Release 35, November 1997
3AI	Aggarwal, B.B., "Apoptosis and Nuclear Factor- $\kappa$ B: A Tale of Association and Dissociation", Biochemical Pharmacology, Vol. 60, pp. 1033-1039 (2000)
3AJ	Baldwin, A.S., "Control of oncogenesis and cancer therapy resistance by the transcription factor NF- $\kappa$ B", The Journal of Clinical Investigation, Vol. 107, No. 3, pp. 241-246 (2001)
3AK	Baldwin, Jr., A.S., "The transcription factor NF- $\kappa$ B and human disease", The Journal of Clinical Investigation, Vol. 107, No. 1, pp. 3-6 (2001)
3AL	Barrot, M. et al., "CREB activity in the nucleus accumbens shell controls gating of behavioral responses to emotional stimuli", Proc. Natl. Acad. Sci., Vol. 99, No. 17, pp. 11435-11440 (2002)
3AM	Basu, S. et al., "The DNA-Dependent Protein Kinase Participates in the Activation of NF $\kappa$ B Following DNA Damage", Biochemical and Biophysical Research Communications, Vol. 247, No. 1, pp. 79-83 (1998)
3AN	Baud, V. et al., "Signal transduction by tumor necrosis factor and its relatives", Trends in Cell Biology, Vol. 11, No. 9, pp. 372-377 (2001)

**EXAMINER****DATE CONSIDERED**

\*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

FORM PTO-1449  
(REV. 7-85)U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE**INFORMATION DISCLOSURE CITATION**

(Use several sheets if necessary)

ATTY. DOCKET NO.  
D0047A CIP  
APPLICATION NO.  
10/712,615  
APPLICANT  
BATTAGLINO ET AL.  
FILING DATE  
NOVEMBER 13, 2003Group  
1745**OTHER DOCUMENTS** (Including Author, Title, Date, Pertinent pages, Etc.)

4AA	Benveniste, H. et al., "Microdialysis — Theory and Application", Progress in Neurobiology, Vol. 135, pp. 195-215 (1990)
4AB	Bowery, N.G. et al., "γ-Aminobutyric Acid <sub>B</sub> Receptors: First of the Functional Metabotropic Heterodimers", The Journal of Pharmacology and Experimental Therapeutics, Vol. 292, No. 1, pp. 2-7 (2000)
4AC	Bunz, F., et al., "Requirement for p53 and p21 to Sustain G <sub>2</sub> Arrest After DNA Damage", Science, Vol. 282, pp. 1497-1501 (1998)
4AD	Bunzow, J.R. et al., "Cloning and expression of a rat D <sub>2</sub> dopamine receptor cDNA", Nature, Vol. 336, pp. 783-787 (1988)
4AE	Charney, D.S. et al., eds., Neurobiology of Mental Illness, Oxford University Press, Inc., publ., pp. ix-xi (table of contents) (1999)
4AF	Cheng, T. et al., "Hematopoietic Stem Cell Quiescence Maintained by p21 <sup>cip1/waf1</sup> ", Science, Vol. 287, pp. 1804-1808 (2000)
4AG	Cryan, J.F. et al., "Assessing antidepressant activity in rodents: recent developments and future needs", Trends in Pharmacological Sciences, Vol. 23, No. 5, pp. 238-245 (2002)
4AH	Dalvi, A. et al., "Murine models of depression", Psychopharmacology, Vol. 147, pp. 14-16 (1999)
4AI	Desdouets, C. et al., "p27: a pleiotropic regulator of cellular phenotype and a target for cell cycle dysregulation in cancer", Pathol. Biol., Vol. 48, pp. 203-210 (2000)
4AJ	Draetta, G.F., "Mammalian G <sub>1</sub> cyclins", Current Opinion in Cell Biology, Vol. 6, pp. 842-846 (1994)
4AK	Feng, Y. et al., "HIV-1 Entry Cofactor: Functional cDNA Cloning of a Seven-Transmembrane, G Protein-Coupled Receptor", Science, Vol. 272, pp. 872-877 (1996)
4AL	Ghosh, S. et al., "NF-κB and Rel Proteins: Evolutionarily Conserved Mediators of Immune Responses", Annu. Rev. Immunol., Vol. 16, pp. 225-260 (1998)
4AM	Guijarro, C. et al., "Transcription factor-κB (NF-κB) and renal disease", Kidney International, Vol. 59, pp. 415-424 (2001)
4AN	Horn, F. et al., "G protein-coupled receptors <i>in silico</i> ", J. Mol. Med., Vol. 76, pp. 464-468 (1998)

**EXAMINER****DATE CONSIDERED**

\*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

FORM PTO-1449  
(REV. 7-85)U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE**INFORMATION DISCLOSURE CITATION**

(Use several sheets if necessary)

ATTY. DOCKET NO.  
D0047A CIP  
APPLICATION NO.  
10/712,615  
APPLICANT  
BATTAGLINO ET AL.  
FILING DATE  
NOVEMBER 13, 2003Group  
1745**OTHER DOCUMENTS** (Including Author, Title, Date, Pertinent pages, Etc.)

5AA	Horn, F. et al., "The Interaction of Class B G Protein-Coupled Receptors with their Hormones", Receptors and Channels, Vol. 5, pp. 305-314 (1998)
5AB	Johnson, G.L. et al., "The G-Protein Family and Their Interaction with Receptors", Endocrine Reviews, Vol. 10, No. 3, pp. 317-331 (1989)
5AC	Jordan, B.A. et al., "G-protein-coupled receptor heterodimerization modulates receptor function", Nature, Vol. 399, pp. 697-700 (1999)
5AD	Kobilka, B.K. et al., "cDNA for the human $\beta_2$ -adrenergic receptor: A protein with multiple membrane-spanning domains and encoded by a gene whose chromosomal location is shared with that of the receptor for platelet-derived growth factor", Proc. Natl. Acad. Sci. USA, Vol. 84, pp. 46-50 (1987)
5AE	Kobilka, B.K. et al., "Cloning, Sequencing, and Expression of the Gene Coding for the Human Platelet $\alpha_2$ -Adrenergic Receptor", Science, Vol. 238, pp.650-656 (1987)
5AF	Lee, D.K. et al., "Discovery and mapping of ten novel G protein-coupled receptor genes", Gene, Vol. 275, pp. 83-91 (2001)
5AG	Lefkowitz, R.J., "Variations on a theme", Nature, Vol. 351, pp. 353-354 (1991)
5AH	Li, S.P. et al., "Differential Distribution of GABA <sub>B1</sub> and GABA <sub>B2</sub> Receptor mRNAs in the Rat Brain", Molecules and Cells, Vol. 16, No. 1, pp. 40-47 (2003)
5AI	Lucki, I., "The forced swimming test as a model for core and component behavioral effects of antidepressant drugs", Behavioural Pharmacology, Vol. 8, pp. 523-532 (1997)
5AJ	Martin, J.H., Neuroanatomy: Text and Atlas, Elsevier Science Publishing Co., publ., pp. vii-xii (table of contents) (1989)
5AK	Martin, S. et al., "Neurotensin Receptor-1 and -3 Complex Modulates the Cellular Signaling of Neurotensin in the HT29 Cell Line", Gastroenterology, Vol. 123, No. 4, pp. 1135-1143 (2002)
5AL	Medema, R.H. et al., "AFX-like Forkhead transcription factors mediate cell-cycle regulation by Ras and PKB through p27 <sup>kip1</sup> ", Nature, Vol. 404, pp. 782-787 (2000)
5AM	Nestler, E.J. et al., "Neurobiology of Depression", Neuron, Vol. 34, pp. 13-25 (2002)
5AN	Parrot, S. et al., "Microdialysis Monitoring of Catecholamines and Excitatory Amino Acids in the Rat and Mouse Brain: Recent Developments Based on Capillary Electrophoresis with Laser-Induced Fluorescence Detection — A Mini-Review", Cellular and Molecular Neurobiology, Vol. 23, Nos. 4/5, pp. 793-804 (2003)

**EXAMINER****DATE CONSIDERED**

\*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

## INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.  
D0047A CIP  
APPLICATION NO.  
10/712,615  
APPLICANT  
BATTAGLINO ET AL.  
FILING DATE  
NOVEMBER 13, 2003Group  
1745

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

6AA	Pfeiffer, M. et al., "Heterodimerization of Somatostatin and Opioid Receptors Cross-modulates Phosphorylation, Internalization, and Desensitization", The Journal of Biological Chemistry, Vol. 277, No. 22, pp. 19762-19772 (2002)
6AB	Pfeiffer, M. et al., "Homo- and Heterodimerization of Somatostatin Receptor Subtypes: Inactivation of sst <sub>3</sub> Receptor Function by Heterodimerization with sst <sub>2A</sub> ", The Journal of Biological Chemistry, Vol. 276, No. 17, pp. 14027-14036 (2001)
6AC	Phillips, A.G. et al., "Amygdalar control of the mesocorticolimbic dopamine system: parallel pathways to motivated behavior", Neuroscience and Biobehavioral Reviews, Vol. 27, pp. 543-554 (2003)
6AD	Robinson, T.E. et al., eds., Microdialysis in the Neurosciences, Elsevier Science Publishers, publ., pp. xvii-xxvi (table of contents) (1991)
6AE	Sands, S.A. et al., "Differential Regulation of GABA <sub>B</sub> Receptor Subunit Expression and Function", The Journal of Pharmacology and Experimental Therapeutics, Vol. 305, No. 1, pp. 191-196 (2003)
6AF	Schafer, K.A., "The Cell Cycle: A Review", Vet. Pathol, Vol. 35, No. 6, pp. 461-478 (1998)
6AG	Sgambato, A. et al., "Multiple Functions of p27 <sup>Kip1</sup> and Its Alterations in Tumor Cells: A Review", Journal of Cellular Physiology, Vol. 183, pp. 18-27 (2000)
6AH	Silverman, N. et al., "NF-κB signaling pathways in mammalian and insect innate immunity", Genes & Development, Vol. 15, pp. 2321-2342 (2001)
6AI	Simon, M.I. et al., "Diversity of G Proteins in Signal Transduction", Science, Vol. 252, pp. 802-808 (1991)
6AJ	Takeda, S. et al., "Identification of G protein-coupled receptor genes from the human genome sequence", FEBS Letters, Vol. 520, pp. 97-101 (2002)
6AK	Terrillon, S. et al., "Oxytocin and Vasopressin V1a and V2 Receptors Form Constitutive Homo- and Heterodimers during Biosynthesis", Molecular Endocrinology, Vol. 17, No. 4, pp. 677-691 (2003)
6AL	Thornberry, N.A. et al., "Caspases: Enemies Within", Science, Vol. 281, pp. 1312-1316 (1998)
6AM	Valen, G. et al., "Nuclear Factor Kappa-B and the Heart", Journal of the American College of Cardiology, Vol. 38, No. 2, pp. 307-314 (2001)
AN	

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.